Short Antibiotic Treatment in High Risk Febrile Neutropenia

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Febrile Neutropenia
Interventions
OTHER

Early Discontinuation of Antibiotics

Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count

OTHER

Standard of Care

Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia

Trial Locations (4)

Unknown

RECRUITING

Alberta Health Services, Edmonton

RECRUITING

London Health Sciences Centre, London

RECRUITING

University Health Network, Toronto

RECRUITING

Vancouver General Hospital, Vancouver

All Listed Sponsors
lead

University Health Network, Toronto

OTHER